Adenine Deoxy Nucleoside

Also known as: Adenosine Adenyldeoxyriboside Deoxyadenosine Desoxyadenosine Adenine Deoxyribonucleoside Adenine Deoxyribose Adenine Nucleoside Adenine Riboside

Therapeutic indications

Adenine Deoxy Nucleoside is indicated for:

Paroxysmal supraventricular tachycardias, Wolff-Parkinson-White Syndrome

Population group: both men and women, only adults (18 years old or older)

Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (Wolff-Parkinson-White Syndrome).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Paroxysmal supraventricular tachycardias, Wolff-Parkinson-White Syndrome

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (Wolff-Parkinson-White Syndrome).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Adenine Deoxy Nucleoside is contraindicated in the following cases:

Second or third degree Atrio-Ventricular (AV) block

at least one of
Second degree atrioventricular block
Complete atrioventricular block

Sick sinus syndrome

Sick sinus syndrome

Chronic obstructive lung disease, bronchospasm, asthma

at least one of
Chronic obstructive lung disease
Bronchospasm
Airway hyperreactivity

Long QT syndrome

at least one of
Long QT syndrome
Prolonged QT interval

Severe hypotension

Hypotension

Decompensated states of heart failure

Decompensated chronic heart failure

Dipyridamole

Dipyridamole

Hypersensitivity to adenosine

Adenosine allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: ADENOCOR Solution for injection
Structured Product Labeling (SPL) 2019: ADENOCARD Solution for injection
Summary of Product Characteristics (SPC) 2021: ADENOSCAN Solution for infusion
< Previous: Overview
Next: Precautions >